{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:15:11Z","timestamp":1762460111857},"reference-count":57,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MBE"],"published-print":{"date-parts":[[2022]]},"abstract":"<abstract>\n\n<sec><title>Background<\/title><p>Interferons (IFNs) have been implemented as anti-tumor immunity agents in clinical trials of glioma, but only a subset of glioblastoma (GBM) patients profits from it. The predictive role of IFNs stimulated genes in GBM needs further exploration to investigate the clinical role of IFNs.<\/p>\n<\/sec>\n\n\n\n<sec><title>Methods<\/title><p>This study screened 526 GBM patients from three independent cohorts. The transcriptome data with matching clinical information were analyzed using R. Immunohistochemical staining data from the Human Protein Atlas and DNA methylation data from MethSurv were used for validation in protein and methylation level respectively.<\/p>\n<\/sec>\n\n\n\n<sec><title>Results<\/title><p>We checked the survival effect of all 491 IFNs response genes, and found 54 genes characterized with significant hazard ratio in overall survival (OS). By protein-protein interaction analysis, 10 hub genes were selected out for subsequent study. And based on the expression of these 10 genes, GBM patients could be divided into two subgroups with significant difference in OS. Furthermore, the least absolute shrinkage and selection operator cox regression model was utilized to construct a multigene risk signature, including <italic>STAT3<\/italic>, <italic>STAT2<\/italic> and <italic>SOCS3<\/italic>, which could serve as an independent prognostic predictor for GBM. The risk model was validated in two independent GBM cohorts. The GBM patients with high risk scores mainly concentrated in the GBM Mesenchymal subtype. The higher risk group was enriched in hypoxia, angiogenesis, EMT, glycolysis and immune pathways, and had increased Macrophage M2 infiltration and high expression of immune checkpoint <italic>CD274<\/italic> (namely <italic>PD-L1<\/italic>).<\/p>\n<\/sec>\n\n\n\n<sec><title>Conclusions<\/title><p>Our findings revealed the three-gene risk model could be an independent prognostic predictor for GBM, and they were crucial participants in immunosuppressive microenvironment of GBM.<\/p>\n<\/sec>\n\n\t\t<\/abstract><\/jats:p>","DOI":"10.3934\/mbe.2022441","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T10:54:05Z","timestamp":1656500045000},"page":"9481-9504","source":"Crossref","is-referenced-by-count":4,"title":["A novel defined risk signature of interferon response genes predicts the prognosis and correlates with immune infiltration in glioblastoma"],"prefix":"10.3934","volume":"19","author":[{"given":"Yong","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"},{"name":"Department of Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"},{"name":"Department of Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"},{"name":"Department of Neurosurgery, Wuxi People's Hospital of Nanjing Medical University, Wuxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"},{"name":"Department of Neurosurgery, Changzhou Wujin People's Hospital, Changzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"},{"name":"Department of Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfa","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianglong","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjie","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2321","reference":[{"key":"key-10.3934\/mbe.2022441-1","doi-asserted-by":"publisher","unstructured":"S. Lapointe, A. Perry, N. A. Butowski, Primary brain tumours in adults, Lancet<\/i>, 392<\/b> (2018), 432-446. DOI: 10.1016\/S0140-6736(18)30990-5","DOI":"10.1016\/S0140-6736(18)30990-5"},{"key":"key-10.3934\/mbe.2022441-2","doi-asserted-by":"publisher","unstructured":"S. A. Grossman, X. Ye, S. Piantadosi, S. Desideri, L. B. Nabors, M. Rosenfeld, et al., Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States, Clin. Cancer Res.<\/i>, 16<\/b> (2010), 2443-2449. DOI: 10.1158\/1078-0432.CCR-09-3106","DOI":"10.1158\/1078-0432.CCR-09-3106"},{"key":"key-10.3934\/mbe.2022441-3","doi-asserted-by":"publisher","unstructured":"M. S. Uddin, A. Al Mamun, B. S. Alghamdi, D. Tewari, P. Jeandet, M. S. Sarwar, et al., Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches, Semin<\/i>. Cancer Biol.<\/i>, 83<\/b> (2022), 100-120. DOI: 10.1016\/j.semcancer.2020.12.015","DOI":"10.1016\/j.semcancer.2020.12.015"},{"key":"key-10.3934\/mbe.2022441-4","doi-asserted-by":"publisher","unstructured":"H. W. Sim, K. L. McDonald, Z. Lwin, E. H. Barnes, M. Rosenthal, M. C. Foote, et al., A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: The VERTU study, Neuro<\/i>l. Oncol.<\/i>, 23<\/b> (2021), 1736-1749. DOI: 10.1093\/neuonc\/noab111","DOI":"10.1093\/neuonc\/noab111"},{"key":"key-10.3934\/mbe.2022441-5","doi-asserted-by":"publisher","unstructured":"X. R. Ni, C. C. Guo, Y. J. Yu, Z. H. Yu, H. P. Cai, W. C. Wu, et al., Combination of levetiracetam and IFN-alpha increased temozolomide efficacy in MGMT-positive glioma, Cancer Chemother. Pharmacol.<\/i>, 86<\/b> (2020), 773-782. DOI: 10.1007\/s00280-020-04169-y","DOI":"10.1007\/s00280-020-04169-y"},{"key":"key-10.3934\/mbe.2022441-6","doi-asserted-by":"publisher","unstructured":"Y. Ochiai, K. Sumi, E. Sano, S. Yoshimura, S. Yamamuro, A. Ogino, et al., Antitumor effects of ribavirin in combination with TMZ and IFN-beta in malignant glioma cells, Oncol. Lett.<\/i>, 20<\/b> (2020), 178. DOI: 10.3892\/ol.2020.12039","DOI":"10.3892\/ol.2020.12039"},{"key":"key-10.3934\/mbe.2022441-7","doi-asserted-by":"publisher","unstructured":"A. Natsume, K. Aoki, F. Ohka, S. Maeda, M. Hirano, A. Adilijiang, et al., Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone, J. Neurooncol.<\/i>, 148<\/b> (2020), 17-27. DOI: 10.1007\/s11060-020-03505-9","DOI":"10.1007\/s11060-020-03505-9"},{"key":"key-10.3934\/mbe.2022441-8","doi-asserted-by":"publisher","unstructured":"K.Yuki, A. Natsume, H. Yokoyama, Y. Kondo, M. Ohno, T. Kato, et al., Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling, Cancer Lett.<\/i>, 284<\/b> (2009), 71-79. DOI: 10.1016\/j.canlet.2009.04.020","DOI":"10.1016\/j.canlet.2009.04.020"},{"key":"key-10.3934\/mbe.2022441-9","doi-asserted-by":"publisher","unstructured":"S. Maeda, H. Wada, Y. Naito, H. Nagano, S. Simmons, Y. Kagawa, et al., Interferon-alpha acts on the S\/G2\/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line, J. Biol. Chem.<\/i>, 289<\/b> (2014), 23786-23795. DOI: 10.1074\/jbc.M114.551879","DOI":"10.1074\/jbc.M114.551879"},{"key":"key-10.3934\/mbe.2022441-10","doi-asserted-by":"publisher","unstructured":"Y. Yang, A. L. Shaffer III, N. T. Emre, M. Ceribelli, M. Zhang, G. Wright, et al., Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma, Cancer Cell<\/i>, 21<\/b> (2012), 723-737. DOI: 10.1016\/j.ccr.2012.05.024","DOI":"10.1016\/j.ccr.2012.05.024"},{"key":"key-10.3934\/mbe.2022441-11","doi-asserted-by":"publisher","unstructured":"M. Ilander, A. Kreutzman, P. Rohon, T. Melo, E. Faber, K. Porkka, et al., Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy, PLoS One<\/i>, 9<\/b> (2014), e87794. DOI: 10.1371\/journal.pone.0087794","DOI":"10.1371\/journal.pone.0087794"},{"key":"key-10.3934\/mbe.2022441-12","doi-asserted-by":"publisher","unstructured":"N. Bacher, V. Raker, C. Hofmann, E. Graulich, M. Schwenk, R. Baumgrass, et al., Interferon-alpha suppresses cAMP to disarm human regulatory T cells, Cancer Res.<\/i>, 73<\/b> (2013), 5647-5656. DOI: 10.1158\/0008-5472.CAN-12-3788","DOI":"10.1158\/0008-5472.CAN-12-3788"},{"key":"key-10.3934\/mbe.2022441-13","doi-asserted-by":"publisher","unstructured":"A. Kane, I. Yang, Interferon-gamma in brain tumor immunotherapy, Neurosurg. Clin. N Am.<\/i>, 21<\/b> (2010), 77-86. DOI: 10.1016\/j.nec.2009.08.011","DOI":"10.1016\/j.nec.2009.08.011"},{"key":"key-10.3934\/mbe.2022441-14","doi-asserted-by":"publisher","unstructured":"V. Galani, S. S. Papadatos, G. Alexiou, A. Galani, A. P. Kyritsis, In vitro<\/i> and in vivo<\/i> preclinical effects of type I IFNs on gliomas, J. Interferon Cytokine Res.<\/i>, 37<\/b> (2017), 139-146. DOI: 10.1089\/jir.2016.0094","DOI":"10.1089\/jir.2016.0094"},{"key":"key-10.3934\/mbe.2022441-15","doi-asserted-by":"publisher","unstructured":"B. X. Wang, R. Rahbar, E. N. Fish, Interferon: Current status and future prospects in cancer therapy, J. Interferon Cytokine Res.<\/i>, 31<\/b> (2011), 545-552. DOI: 10.1089\/jir.2010.0158","DOI":"10.1089\/jir.2010.0158"},{"key":"key-10.3934\/mbe.2022441-16","doi-asserted-by":"publisher","unstructured":"J. Lei, M. H. Zhou, F. C. Zhang, K. Wu, S. W. Liu, H. Q. Niu, Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma, Aging (Albany NY)<\/i>, 13<\/b> (2021), 12086-12098. DOI: 10.18632\/aging.202915","DOI":"10.18632\/aging.202915"},{"key":"key-10.3934\/mbe.2022441-17","doi-asserted-by":"publisher","unstructured":"F. J. Reu, S. I. Bae, L. Cherkassky, D. W. Leaman, D. Lindner, N. Beaulieu, et al., Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation, J. Clin. Oncol.<\/i>, 24<\/b> (2006), 3771-3779. DOI: 10.1200\/JCO.2005.03.4074","DOI":"10.1200\/JCO.2005.03.4074"},{"key":"key-10.3934\/mbe.2022441-18","doi-asserted-by":"publisher","unstructured":"Y. Yang, Y. Zhou, J. Hou, C. Bai, Z. Li, J. Fan, et al., Hepatic IFIT3 predicts interferon-alpha therapeutic response in patients of hepatocellular carcinoma, Hepatology<\/i>, 66<\/b> (2017), 152-166. DOI: 10.1002\/hep.29156","DOI":"10.1002\/hep.29156"},{"key":"key-10.3934\/mbe.2022441-19","doi-asserted-by":"publisher","unstructured":"Z. Zhao, F. Meng, W. Wang, Z. Wang, C. Zhang, T. Jiang, Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas, Sci. Data<\/i>, 4<\/b> (2017), 170024. DOI: 10.1038\/sdata.2017.24","DOI":"10.1038\/sdata.2017.24"},{"key":"key-10.3934\/mbe.2022441-20","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas Research N, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature<\/i>, 455<\/b> (2008), 1061-1068. DOI: 10.1038\/nature07385","DOI":"10.1038\/nature07385"},{"key":"key-10.3934\/mbe.2022441-21","doi-asserted-by":"publisher","unstructured":"H. Mizuno, K. Kitada, K. Nakai, A. Sarai, PrognoScan: A new database for meta-analysis of the prognostic value of genes, BMC Med. Genomics<\/i>, 2<\/b> (2009), 18. DOI: 10.1186\/1755-8794-2-18","DOI":"10.1186\/1755-8794-2-18"},{"key":"key-10.3934\/mbe.2022441-22","doi-asserted-by":"publisher","unstructured":"V. Modhukur, T. Iljasenko, T. Metsalu, K. Lokk, T. Laisk-Podar, et al., MethSurv: A web tool to perform multivariable survival analysis using DNA methylation data, Epigenomics<\/i>, 10<\/b> (2018), 277-288. DOI: 10.2217\/epi-2017-0118","DOI":"10.2217\/epi-2017-0118"},{"key":"key-10.3934\/mbe.2022441-23","doi-asserted-by":"publisher","unstructured":"A. Liberzon, C. Birger, H. Thorvaldsd\u00f3ttir, M. Ghandi, J. P. Mesirov, P. Tamayo, The molecular signatures database (MSigDB) hallmark gene set collection, Cell Syst.<\/i>, 1<\/b> (2015), 417-425. DOI: 10.1016\/j.cels.2015.12.004","DOI":"10.1016\/j.cels.2015.12.004"},{"key":"key-10.3934\/mbe.2022441-24","doi-asserted-by":"publisher","unstructured":"T. Li, J. Fu, Z. Zeng, D. Cohen, J. Li, Q. Chen, et al., TIMER2.0 for analysis of tumor-infiltrating immune cells, Nucleic Acids Res.<\/i>, 48<\/b> (2020), W509-W514. DOI: 10.1093\/nar\/gkaa407","DOI":"10.1093\/nar\/gkaa407"},{"key":"key-10.3934\/mbe.2022441-25","doi-asserted-by":"publisher","unstructured":"A. M. Newman, C. L. Liu, M. R. Green, A. J. Gentles, W. Feng, Y. Xu, et al., Robust enumeration of cell subsets from tissue expression profiles, Nat. Methods<\/i>, 12<\/b> (2015), 453-457. DOI: 10.1038\/nmeth.3337","DOI":"10.1038\/nmeth.3337"},{"key":"key-10.3934\/mbe.2022441-26","doi-asserted-by":"publisher","unstructured":"M. Uhl\u00e9n, L. Fagerberg, B. M. Hallstr\u00f6m, C. Lindskog, P. Oksvold, A. Mardinoglu, et al., Proteomics. Tissue-based map of the human proteome, Science<\/i>, 347<\/b> (2015), 1260419. DOI: 10.1126\/science.1260419","DOI":"10.1126\/science.1260419"},{"key":"key-10.3934\/mbe.2022441-27","doi-asserted-by":"publisher","unstructured":"W. Ji, Y. Liu, B. Xu, J. Mei, C. Cheng, Y. Xiao, et al., Bioinformatics analysis of expression profiles and prognostic values of the signal transducer and activator of transcription family genes in glioma, Front. Genet.<\/i>, 12<\/b> (2021), 625234. DOI: 10.3389\/fgene.2021.625234","DOI":"10.3389\/fgene.2021.625234"},{"key":"key-10.3934\/mbe.2022441-28","doi-asserted-by":"publisher","unstructured":"K. Dzobo, D. A. Senthebane, C. Ganz, N. E. Thomford, A. Wonkam, C. Dandara, Advances in therapeutic targeting of cancer stem cells within the tumor microenvironment: An updated review, Cells<\/i>, 9<\/b> (2020), 1896. DOI: 10.3390\/cells9081896","DOI":"10.3390\/cells9081896"},{"key":"key-10.3934\/mbe.2022441-29","doi-asserted-by":"publisher","unstructured":"C. Hou, Y. Ishi, H. Motegi, M. Okamoto, Y. Ou, J. Chen, et al., Overexpression of CD44 is associated with a poor prognosis in grade II\/III gliomas, J. Neurooncol.<\/i>, 145<\/b> (2019), 201-210. DOI: 10.1007\/s11060-019-03288-8","DOI":"10.1007\/s11060-019-03288-8"},{"key":"key-10.3934\/mbe.2022441-30","doi-asserted-by":"publisher","unstructured":"A. Vakilian, H. Khorramdelazad, P. Heidari, Z. S. Rezaei, G. Hassanshahi, CCL2\/CCR2 signaling pathway in glioblastoma multiforme, Neurochem. Int.<\/i>, 103<\/b> (2017), 1-7. DOI: 10.1016\/j.neuint.2016.12.013","DOI":"10.1016\/j.neuint.2016.12.013"},{"key":"key-10.3934\/mbe.2022441-31","unstructured":"S. H. Hayes, G. M. Seigel, Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues, Int. J. Clin. Exp. Pathol.<\/i>, 2<\/b> (2009), 553-560."},{"key":"key-10.3934\/mbe.2022441-32","doi-asserted-by":"publisher","unstructured":"T. Cartwright, N. D. Perkins, C. L. Wilson, NFKB1: A suppressor of inflammation, ageing and cancer, Febs. J.<\/i>, 283<\/b> (2016), 1812-1822. DOI: 10.1111\/febs.13627","DOI":"10.1111\/febs.13627"},{"key":"key-10.3934\/mbe.2022441-33","doi-asserted-by":"publisher","unstructured":"Q. Guo, X. Xiao, J. Zhang, MYD88 is a potential prognostic gene and immune signature of tumor microenvironment for gliomas, Front. Oncol.<\/i>, 11<\/b> (2021), 654388. DOI: 10.3389\/fonc.2021.654388","DOI":"10.3389\/fonc.2021.654388"},{"key":"key-10.3934\/mbe.2022441-34","doi-asserted-by":"publisher","unstructured":"Y. E. Hadisaputri, T. Miyazaki, T. Yokobori, M. Sohda, M. Sakai, D. Ozawa, et al., TNFAIP3 overexpression is an independent factor for poor survival in esophageal squamous cell carcinoma, Int. J. Oncol.<\/i>, 50<\/b> (2017), 1002-1010. DOI: 10.3892\/ijo.2017.3869","DOI":"10.3892\/ijo.2017.3869"},{"key":"key-10.3934\/mbe.2022441-35","doi-asserted-by":"publisher","unstructured":"M. P. Ventero, M. Fuentes-Baile, C. Quereda, E. Perez-Valeciano, C. Alenda, P. Garcia-Morales, et al., Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3, PLoS One<\/i>, 14<\/b> (2019), e0212581. DOI: 10.1371\/journal.pone.0212581","DOI":"10.1371\/journal.pone.0212581"},{"key":"key-10.3934\/mbe.2022441-36","doi-asserted-by":"publisher","unstructured":"O. Gusyatiner, M. E. Hegi, Glioma epigenetics: From subclassification to novel treatment options, Semin. Cancer Biol.<\/i>, 51<\/b> (2018), 50-58. DOI: 10.1016\/j.semcancer.2017.11.010","DOI":"10.1016\/j.semcancer.2017.11.010"},{"key":"key-10.3934\/mbe.2022441-37","doi-asserted-by":"publisher","unstructured":"R. Chaligne, F. Gaiti, D. Silverbush, J. S. Schiffman, H. R. Weisman, L. Kluegel, et al., Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states, Nat. Genet.<\/i>, 53<\/b> (2021), 1469-1479. DOI: 10.1038\/s41588-021-00927-7","DOI":"10.1038\/s41588-021-00927-7"},{"key":"key-10.3934\/mbe.2022441-38","doi-asserted-by":"publisher","unstructured":"J. Lu, Z. Xu, H. Duan, H. Ji, Z. Zhen, B. Li, et al., Tumor-associated macrophage interleukin-beta promotes glycerol-3-phosphate dehydrogenase activation, glycolysis and tumorigenesis in glioma cells, Cancer Sci.<\/i>, 111<\/b> (2020), 1979-1990. DOI: 10.1111\/cas.14408","DOI":"10.1111\/cas.14408"},{"key":"key-10.3934\/mbe.2022441-39","doi-asserted-by":"publisher","unstructured":"J. Ye, Y. Yang, J. Jin, M. Ji, Y. Gao, Y. Feng, et al., Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma, Bioact. Mater.<\/i>, 5<\/b> (2020), 694-708. DOI: 10.1016\/j.bioactmat.2020.05.001","DOI":"10.1016\/j.bioactmat.2020.05.001"},{"key":"key-10.3934\/mbe.2022441-40","doi-asserted-by":"publisher","unstructured":"D. Akhavan, D. Alizadeh, D. Wang, M. R. Weist, J. K. Shepphird, C. E. Brown, CAR T cells for brain tumors: Lessons learned and road ahead, Immunol. Rev.<\/i>, 290<\/b> (2019), 60-84. DOI: 10.1111\/imr.12773","DOI":"10.1111\/imr.12773"},{"key":"key-10.3934\/mbe.2022441-41","doi-asserted-by":"publisher","unstructured":"C. Neftel, J. Laffy, M. G. Filbin, T. Hara, M. E. Shore, G. J. Rahme, et al., An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell<\/i>, 178<\/b> (2019), 835-849. DOI: 10.1016\/j.cell.2019.06.024","DOI":"10.1016\/j.cell.2019.06.024"},{"key":"key-10.3934\/mbe.2022441-42","doi-asserted-by":"publisher","unstructured":"J. Chen, Y. Li, Q. Zheng, C. Bao, J. He, B. Chen, et al., Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer, Cancer Lett.<\/i>, 388<\/b> (2017), 208-219. DOI: 10.1016\/j.canlet.2016.12.006","DOI":"10.1016\/j.canlet.2016.12.006"},{"key":"key-10.3934\/mbe.2022441-43","unstructured":"F. M. Tian, F. Q. Meng, X. B. Wang, Overexpression of long-noncoding RNA ZFAS1 decreases survival in human NSCLC patients, Eur. Rev. Med. Pharmacol. Sci.<\/i>, 20<\/b> (2016), 5126-5131."},{"key":"key-10.3934\/mbe.2022441-44","doi-asserted-by":"publisher","unstructured":"M. Zhou, Z. Zhang, S. Bao, P. Hou, C. Yan, J. Su, et al., Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer, Brief Bioinform.<\/i>, 22<\/b> (2021), bbaa047. DOI: 10.1093\/bib\/bbaa047","DOI":"10.1093\/bib\/bbaa047"},{"key":"key-10.3934\/mbe.2022441-45","doi-asserted-by":"publisher","unstructured":"Y. Ye, Q. Dai, S. Li, J. He, H. Qi, A novel defined risk signature of the ferroptosis-related genes for predicting the prognosis of ovarian cancer, Front. Mol. Biosci.<\/i>, 8<\/b> (2021), 645845. DOI: 10.3389\/fmolb.2021.645845","DOI":"10.3389\/fmolb.2021.645845"},{"key":"key-10.3934\/mbe.2022441-46","doi-asserted-by":"publisher","unstructured":"N. Au-Yeung, R. Mandhana, C. M. Horvath, Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway, Jakstat<\/i>, 2<\/b> (2013), e23931. DOI: 10.4161\/jkst.23931","DOI":"10.4161\/jkst.23931"},{"key":"key-10.3934\/mbe.2022441-47","doi-asserted-by":"publisher","unstructured":"J. Xu, M. H. Lee, M. Chakhtoura, B. L. Green, K. P. Kotredes, R. W. Chain, et al., STAT2 is required for TLR-induced murine dendritic cell activation and cross-presentation, J. Immunol.<\/i>, 197<\/b> (2016), 326-336. DOI: 10.4049\/jimmunol.1500152","DOI":"10.4049\/jimmunol.1500152"},{"key":"key-10.3934\/mbe.2022441-48","doi-asserted-by":"publisher","unstructured":"L. Wang, D. Xu, L. Cai, J. Dai, Y. Li, H. Xu, Expression and survival analysis of the STAT gene family in diffuse gliomas using integrated bioinformatics, Curr. Res. Transl. Med.<\/i>, 69<\/b> (2021), 103274. DOI: 10.1016\/j.retram.2020.103274","DOI":"10.1016\/j.retram.2020.103274"},{"key":"key-10.3934\/mbe.2022441-49","doi-asserted-by":"publisher","unstructured":"K. Swiatek-Machado, B. Kaminska, STAT signaling in glioma cells, Adv. Exp. Med. Biol.<\/i>, 986<\/b> (2013), 189-208. DOI: 10.1007\/978-94-007-4719-7_10","DOI":"10.1007\/978-94-007-4719-7_10"},{"key":"key-10.3934\/mbe.2022441-50","doi-asserted-by":"publisher","unstructured":"Y. Wang, Y. Shen, S. Wang, Q. Shen, X. Zhou, The role of STAT3 in leading the crosstalk between human cancers and the immune system, Cancer Lett.<\/i>, 415<\/b> (2018), 117-128. DOI: 10.1016\/j.canlet.2017.12.003","DOI":"10.1016\/j.canlet.2017.12.003"},{"key":"key-10.3934\/mbe.2022441-51","doi-asserted-by":"publisher","unstructured":"K. V. Myers, K. J. Pienta, S. R. Amend, Cancer cells and M2 macrophages: Cooperative invasive ecosystem engineers, Cancer Control<\/i>, 27<\/b> (2020), 1073274820911058. DOI: 10.1177\/1073274820911058","DOI":"10.1177\/1073274820911058"},{"key":"key-10.3934\/mbe.2022441-52","doi-asserted-by":"publisher","unstructured":"R. Mahony, S. Ahmed, C. Diskin, N. J. Stevenson, SOCS3 revisited: A broad regulator of disease, now ready for therapeutic use, Cell Mol. Life Sci.<\/i>, 73<\/b> (2016), 3323-3336. DOI: 10.1007\/s00018-016-2234-x","DOI":"10.1007\/s00018-016-2234-x"},{"key":"key-10.3934\/mbe.2022441-53","doi-asserted-by":"publisher","unstructured":"Y. Yu, S. K. Sung, C. H. Lee, M. Ha, J. Kang, E. J. Kwon, et al., SOCS3 is related to cell proliferation in neuronal tissue: An integrated analysis of bioinformatics and experiments, Front. Genet.<\/i>, 12<\/b> (2021), 743786. DOI: 10.3389\/fgene.2021.743786","DOI":"10.3389\/fgene.2021.743786"},{"key":"key-10.3934\/mbe.2022441-54","doi-asserted-by":"publisher","unstructured":"B. C. McFarland, M. P. Marks, A. L. Rowse, S. C. Fehling, M. Gerigk, H. Qin, et al., Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma, Oncotarget<\/i>, 7<\/b> (2016), 20621-20635. DOI: 10.18632\/oncotarget.7992","DOI":"10.18632\/oncotarget.7992"},{"key":"key-10.3934\/mbe.2022441-55","doi-asserted-by":"publisher","unstructured":"H. Zhou, R. Miki, M. Eeva, F. M. Fike, D. Seligson, L. Yang, et al., Reciprocal regulation of SOCS1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme, Clin. Cancer Res.<\/i>, 13<\/b> (2007), 2344-2353. DOI: 10.1158\/1078-0432.CCR-06-2303","DOI":"10.1158\/1078-0432.CCR-06-2303"},{"key":"key-10.3934\/mbe.2022441-56","doi-asserted-by":"publisher","unstructured":"D. F. Quail, J. A. Joyce, The microenvironmental landscape of brain tumors, Cancer Cell<\/i>, 31<\/b> (2017), 326-341. DOI: 10.1016\/j.ccell.2017.02.009","DOI":"10.1016\/j.ccell.2017.02.009"},{"key":"key-10.3934\/mbe.2022441-57","doi-asserted-by":"publisher","unstructured":"Y. Masugi, R. Nishihara, J. Yang, K. Mima, A. Da Silva, Y. Shi, et al., Tumour CD274 (PD-L1) expression and T cells in colorectal cancer, Gut<\/i>, 66<\/b> (2017), 1463-1473. DOI:10.1136\/gutjnl-2016-311421","DOI":"10.1136\/gutjnl-2016-311421"}],"container-title":["Mathematical Biosciences and Engineering"],"original-title":[],"link":[{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2022441?viewType=html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T01:50:14Z","timestamp":1657763414000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2022441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3934\/mbe.2022441","relation":{},"ISSN":["1551-0018"],"issn-type":[{"value":"1551-0018","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}